



SONGKLANAGARIND HOSPITAL, FACULTY OF MEDICINE
PRINCE OF SONGKLA UNIVERSITY
HATYAI SONGKHLA, THAILAND

HOSPITAL-BASED TUMOR REGISTRY

SONGKLANAGARIND HOSPITAL ANNUAL REPORT 2017

EDITED BY
PARADEE PRECHAWITTAYAKUL, B.Sc.



CANCER INFORMATION CENTER
<http://medinfo2.psu.ac.th/cancer>

HOSPITAL-BASED TUMOR REGISTRY

SONGKLANAGARIND HOSPITAL ANNUAL REPORT 2017

EDITED BY
PARADEE PRECHAWITTAYAKUL, B.Sc.

CANCER INFORMATION CENTER
<http://medinfo2.psu.ac.th/cancer>

CONTENTS

Contents.....	i
Cancer Registry Staff	IV
Flow Chart of the Songklanagarind Cancer Registry.....	V
Flow Chart of the Songklanagarind Cancer Registry Report.....	VI
Summary	VII
Table 1: Number of patients in Songklanagarind hospital.....	1
Table 2: Patient categories of diagnosis and treatment.....	2
Table 3: Distribution of primary health care services.....	2
Table 4: Cancer cases by province of residence.....	5
Table 5: Distribution of all newly diagnosed cancer cases by age and gender.....	6
Table 6: Distribution of cases according to method of diagnosis.....	7
Table 7: Percentage of morphologically verified cases (%MV)	7
Table 8: The 10 leading sites of cancer in all gender.....	10
Table 9: The 10 leading sites of cancer in males.....	11
Table 10: The 10 leading sites of cancer in females.....	12
Table 11: Malignancy in childhood.....	13

COMMON CANCERS

Oral Cavity Cancer

Table 12: Staging.....	14
------------------------	----

Esophageal Cancer

Table 13: Staging.....	15
------------------------	----

Colon and Rectum Cancer

Table 14: Staging.....	16
------------------------	----

Lung Cancer

Table 15: Staging	17
-------------------------	----

Breast Cancer (Excluding in Situ)

Table 16: Staging.....	18
------------------------	----

Cervical Cancer (Excluding in Situ)

Table 17: Staging.....	19
------------------------	----

Table 18: Sex and age distribution according to primary site	20
--	----

Table 19: Histological types	33
------------------------------------	----

APPENDIX: Definitions	49
------------------------------------	----


ILLUSTRATIONS

FIGURE 1: Trend of new cancer cases in Songklanagarind hospital	1
FIGURE 2: New cancer cases as a percentage year on year	1
FIGURE 3: Number of new cancer cases by month	2
FIGURE 4: Percentage of cancers received initial diagnosis or treatment.....	2
FIGURE 5: Percentage of patient payment used	3
FIGURE 6: Trends of patients payment used; percentage	4
FIGURE 7: Distribution of religion in cancer patients: percentage	4
FIGURE 8: Percentage of patient by residence	5
FIGURE 9: Age distribution of all malignancies	6
FIGURE 10: Methods of diagnosis	7
FIGURE 11: The 10 leading Sites of cancer in all gender	10
FIGURE 12: The 10 leading sites of cancer in males	11
FIGURE 13: Trends of five leading sites in males: number.....	11
FIGURE 14: The 10 leading sites of cancer in females	12
FIGURE 15: Trends of five leading sites in females: number.....	12
FIGURE 16: Age distribution of all malignancies in childhood	13
<i>Oral Cavity Cancer</i>	
FIGURE 17: Distribution of subsites	14
<i>Esophageal Cancer</i>	
FIGURE 18: Distribution of subsites	15
<i>Colon and Rectum Cancer</i>	
FIGURE 19: Distribution of subsites	16
FIGURE 20: Staging trends; percentage	16
<i>Lung Cancer</i>	
FIGURE 21: Distribution of subsites	17
<i>Breast Cancer (Excluding in Situ)</i>	
FIGURE 22: Distribution of subsites	18
FIGURE 23: Staging trends of female breast cancer: percentage	18
<i>Cervical Cancer (Excluding in Situ)</i>	
FIGURE 24: Staging trends of cervical cancer: percentage	19


CANCER REGISTRY STAFF

MISS PARADEE	PRECHAWITTAYAKUL	NURSE
MISS BENJAPORN	CHUMSEANG	REGISTRAR
MRS. RATTANA	SUWANNO	REGISTRAR
MISS WANDEE	SRITONGKAEW	REGISTRAR
MRS. PARICHAD	PANCHALERM	REGISTRAR

FLOW CHART OF SONGKLANAGARIND TUMOR REGISTRY



FLOW CHART OF SONGKLANAGARIND CANCER REGISTRY REPORT



S U M M A R Y

From January to December 2017, among 1,019,375 patients who attended Songklanagarind Hospital, 5,881 cases were new cancer patients. Males accounted for 2,787 cancer cases (47.4%). The three most payment used were universal coverage Scheme (52.4%) government/state enterprise (21.0%) and self payment (7.3%) respectively. The three most common sites, disregarding gender, were breast (700 cases, 11.9%), lung (624 cases, 10.6%), and colon and rectum (482 cases, 8.2%). The three most common primary sites in males were the lung (14.7%), liver (11.9%) and colon & rectum (9.7%). The three most common primary sites in females were the breast (22.6%), uterine cervix (12.2%) and thyroid (9.6%). There were 128 cases (2.2%) of childhood malignancy of which the most common type was leukemia.

The percentage of histologically confirmed cases was 86.3% in males and 93.9% in females. The three most common provinces of residence were Songkhla, Nakhon Si Thammarat and Phattalung.

TABLE 1: NUMBER OF PATIENTS IN SONGKLANAGARIND HOSPITAL

TYPE OF PATIENTS	NUMBER OF CASES
Total patients at outpatient department	1,019,375
New patients of hospital	21,265
New cancer patients	5,881

The new cancers were 27.7% of new patients of Songklanakarind hospital in year 2017.

FIGURE 1: TREND OF NEW CANCER CASES IN SONGKLANAGARIND HOSPITAL




FIGURE 2: NEW CANCER CASES AS A PERCENTAGE OF YEAR ON YEAR




FIGURE 3: NUMBER OF NEW CANCER CASES BY MONTH




TABLE 2: PATIENT CATEGORIES OF DIAGNOSIS AND TREATMENT

PATIENT CATEGORY	NUMBER	PERCENT
Diagnosed(other), treated (here)	1,922	32.7%
Diagnosed(here), treated (here)	1,193	20.3%
Diagnosed(other), treated (here&other)	1,032	17.5%
Diagnosed(here), no treatment	429	7.3%
Diagnosed(other), treated (other)	354	6.0%
Diagnosed(other), no treatment (here&other)	951	16.2%
Total	5,881	100.0%

*Here means Songklanagarind hospital.

FIGURE 4: PERCENTAGE OF CANCERS RECEIVED INITIAL DIAGNOSIS OR TREATMENT




TABLE 3: DISTRIBUTION OF PATIENT PAYMENT USED

PAYMENT CATEGORIES	%	No.
Universal Coverage Scheme(UCS)	52.4%	3,083
Government/ State Enterprise Officer(OFC)	21.0%	1,233
Self Payment	7.3%	428
Social Security Scheme(SSS)	7.7%	450
Local Administrative Organization	2.6%	150
Alien Worker	0.3%	16
Not specified	8.9%	521
	100.0%	5,881

FIGURE 5: PERCENTAGE OF PATIENT PAYMENT USED




FIGURE 6: TRENDS OF PATIENT PAYMENT USED: PERCENTAGE




FIGURE 7: DISTRIBUTION OF RELIGION IN CANCER PATIENTS: PERCENTAGE




TABLE 4: CANCER CASES BY PROVINCE OF RESIDENCE

AREA	NUMBER	PERCENT
Songkhla	1,447	24.6%
Nakhon Si Thammarat	1,060	18.0%
Phatthalung	616	10.5%
Trang	513	8.7%
Narathiwat	354	5.5%
Pattani	323	6.0%
Surat Thani	258	4.4%
Yala	258	4.4%
Phuket	258	3.9%
Satun	236	4.0%
Krabi	232	4.4%
Phangnga	167	2.8%
Chumphon	62	1.1%
Ranong	41	0.7%
Non-Southern Provinces	56	1.0%
	5,881	100.0%



FIGURE 8: PERCENTAGE OF PATIENT BY RESIDENCE




TABLE 5: DISTRIBUTION OF ALL NEWLY DIAGNOSED CANCER CASES BY AGE AND GENDER

AGE GROUP	Males		Females		Total	
	No	% OF ALL CANCER	No	% OF ALL CANCER	No	% OF ALL CANCER
0-	25	0.4%	23	0.4%	48	0.8%
5-	22	0.4%	7	0.1%	29	0.5%
10-	24	0.4%	27	0.5%	51	0.9%
15-	19	0.3%	19	0.3%	38	0.6%
20-	29	0.5%	46	0.8%	75	1.3%
25-	29	0.5%	71	1.2%	100	1.7%
30-	49	0.8%	117	2.0%	166	2.8%
35-	69	1.2%	185	3.1%	254	4.3%
40-	133	2.3%	250	4.3%	383	6.5%
45-	189	3.2%	341	5.8%	530	9.0%
50-	263	4.5%	387	6.6%	650	11.1%
55-	378	6.4%	385	6.5%	763	13.0%
60-	378	6.4%	369	6.3%	747	12.7%
65-	402	6.8%	294	5.0%	696	11.8%
70-	275	4.7%	216	3.7%	491	8.3%
75-	258	4.4%	150	2.6%	408	6.9%
80-	148	2.5%	131	2.2%	279	4.7%
85+	97	1.6%	76	1.3%	173	2.9%
	2,787	47.4%	3,094	52.6%	5,881	100.0%

Male age; mean = 59.84, median = 62

Female age; mean = 54.93, median = 56

FIGURE 9: AGE DISTRIBUTION OF ALL MALIGNANCIES



TABLE 6: DISTRIBUTION OF CASES ACCORDING TO METHOD OF DIAGNOSIS

METHOD OF DIAGNOSIS	MALE		FEMALE	
	NO.	% IN MALES	NO.	% IN FEMALES
Clinical only	11	0.4%	18	0.6%
Clinical investigation and imaging	238	8.5%	134	4.3%
Specific biochemistry	133	4.8%	38	1.2%
Cytology or hematology	46	1.7%	45	1.5%
Histology of metastasis	39	1.4%	22	0.7%
Histology of primary	2320	83.2%	2837	91.7%
	2,787	100.0%	3,094	100.0%

FIGURE 10: METHODS OF DIAGNOSIS




TABLE 7: PERCENTAGE OF MORPHOLOGICALLY VERIFIED CASES (%MV)

ICD-10	Primary sites	Male			Female			All		
		Total	Number of Micro. Verified	%MV In Males	Total	Number of Micro. Verified	%MV In Females	Total	Number of Micro. Verified	%MV All gender
C00	Lip	1	1	100.0%	2	2	100.0%	3	3	100.0%
C01-C02	Tongue	97	97	100.0%	36	35	97.2%	133	132	99.2%
C03-C06	Mouth	96	96	100.0%	35	35	100.0%	131	131	100.0%
C07-C08	Salivary gland	12	12	100.0%	18	18	100.0%	30	30	100.0%
C09	Tonsil	44	44	100.0%	5	5	100.0%	49	49	100.0%
C10	Oropharynx	22	22	100.0%	0	0	0	22	22	100.0%
C11	Nasopharynx	95	95	100.0%	26	26	100.0%	121	121	100.0%

TABLE 7: (CONT) PERCENTAGE OF MORPHOLOGICALLY VERIFIED CASES (%MV)

ICD-10	Primary sites	Male			Female			All		
		Total	Number of Micro. Verified	%MV In Males	Total	Number of Micro. Verified	%MV In Females	Total	Number of Micro. Verified	%MV All gender
C12-C13	Hypopharynx	65	63	96.9%	3	3	100.0%	68	66	97.1%
C14	Pharynx, unspecified	11	10	90.9%	7	7	100.0%	18	17	94.4%
C15	Esophagus	173	169	97.7%	16	15	93.8%	189	184	97.4%
C16	Stomach	55	53	96.4%	26	23	88.5%	81	76	93.8%
C17	Small intestine	9	9	100.0%	4	3	75.0%	13	12	92.3%
C18	Colon	110	107	97.3%	100	92	92.0%	210	199	94.8%
C19-C20	Rectum	161	157	97.5%	111	110	99.1%	272	267	98.2%
C21	Anus	9	9	100.0%	5	5	100.0%	14	14	100.0%
C22	Liver	331	70	21.1%	137	50	36.5%	468	120	25.6%
C23-C24	Gallbladder etc.	23	20	87.0%	40	38	95.0%	63	58	92.1%
C25	Pancreas	44	26	59.1%	45	34	75.6%	89	60	67.4%
C30-31	Nose, sinuses etc.	20	20	100.0%	13	13	100.0%	33	33	100.0%
C32	Larynx	99	98	99.0%	3	3	100.0%	102	101	99.0%
C33-C34	Bronchus and lung	410	373	91.0%	214	192	89.7%	624	565	90.5%
C37-C38	Other thoracic organs	9	8	88.9%	5	4	80.0%	14	12	85.7%
C40-C41	Bone	15	13	86.7%	16	14	87.5%	31	27	87.1%
C43	Melanoma of skin	13	13	100.0%	12	12	100.0%	25	25	100.0%
C44	Other skin	50	49	98.0%	55	54	98.2%	105	103	98.1%
C46	Kaposi sarcoma	1	0	100.0%	0	0	0	1	1	100.0%
C47; C49	Connective and soft tissue	41	40	97.6%	32	30	93.8%	73	70	95.9%
C50	Breast	2	2	100.0%	698	688	98.6%	700	690	98.6%
C51	Vulva	0	0	0	18	18	100.0%	18	18	100.0%
C52	Vagina	0	0	0	3	3	100.0%	3	3	100.0%
C53	Cervix uteri	0	0	0	377	372	98.7%	377	372	98.7%



TABLE 7: (CONT) PERCENTAGE OF MORPHOLOGICALLY VERIFIED CASES (%MV)

ICD-10	Primary sites	Male			Female			All		
		Total	Number of Micro. Verified	%MV In Males	Total	Number of Micro. Verified	%MV In Females	Total	Number of Micro. Verified	%MV All gender
C54	Corpus uteri	0	0	0	186	183	98.4%	186	183	
C55	Uterus unspecified	0	0	0	18	18	100.0%	18	18	100.0%
C56	Ovary	0	0	0	196	188	95.9%	196	188	95.9%
C57	Other female genital	0	0	0	4	4	100.0%	4	4	100.0%
C58	Placenta	0	0	0	4	4	100.0%	4	4	100.0%
C60	Penis	13	12	92.3%	0	0	0	13	12	92.3%
C61	Prostate	161	148	91.9%	0	0	0	161	148	91.9%
C62	Testis	14	14	100.0%	0	0	0	14	14	100.0%
C63	Other male genital	0	0	0	0	0	0	0	0	0
C64	Kidney	54	44	81.5%	23	19	82.6%	77	63	81.8%
C65	Renal pelvis	3	2	66.7%	2	1	50.0%	5	3	60.0%
C66	Ureter	2	2	100.0%	0	0	0	2	2	100.0%
C67	Bladder	78	76	97.4%	12	12	100.0%	90	88	97.8%
C68	Other urinary organs	1	1	100.0%	0	0	0	1	1	100.0%
C69	Eye	9	8	88.9%	5	5	100.0%	14	13	92.9%
C70-C72	Brain, nervous system	55	51	92.7%	34	34	100.0%	89	85	95.5%
C73	Thyroid	61	61	100.0%	297	293	98.7%	358	354	98.9%
C74	Adrenal gland	7	7	100.0%	2	2	100.0%	9	9	100.0%
C75	Other endocrine	0	0	0	1	0	0.0%	1	0	0.0%
C81	Hodgkin's disease	10	10	100.0%	19	19	100.0%	29	29	100.0%
C82-C85, C96	Non-Hodgkin lymphoma	147	147	100.0%	87	87	100.0%	234	234	100.0%
C90	Multiple myeloma	24	24	100.0%	22	22	100.0%	46	46	100.0%
C91	Lymphoid leukemia	23	23	100.0%	18	18	100.0%	41	41	100.0%
C92-C94	Myeloid leukemia	35	35	100.0%	34	34	100.0%	69	69	100.0%

TABLE 7: (CONT) PERCENTAGE OF MORPHOLOGICALLY VERIFIED CASES (%MV)

ICD-10	Primary sites	Male			Female			All		
		Total	Number of Micro. Verified	%MV In Males	Total	Number of Micro. Verified	%MV In Females	Total	Number of Micro. Verified	%MV All gender
C95	Leukemia unspecified	5	5	100.0%	2	2	100.0%	7	7	100.0%
C96	Langerhans-cell histiocytosis	2	2	100.0%	2	2	100.0%	4	4	100.0%
O&U	Other and unspecified	58	49	84.5%	62	51	82.3%	120	100	83.3%
D46	Myelodysplastic syndromes	2	2	100.0%	2	2	100.0%	4	4	100.0%
D47	Myeloproliferative disorders	5	5	100.0%	0	0	0	5	5	100.0%
	TOTAL	2,787	2,404	86.3%	3,094	2,904	93.9%	5,881	5,308	90.3%

TABLE 8: THE 10 LEADING SITES OF CANCER IN ALL GENDER

ICD-10	PRIMARY SITE(Short title used)	NO.	% OF ALL CANCER
C50	Breast	700	11.9%
C33-C34	Bronchus and lung	624	10.6%
C18-20	Colon and Rectum	482	8.2%
C22	Liver	468	8.0%
C53	Cervix uteri	377	6.4%
C73	Thyroid	358	6.1%
C01-06	Oral cavity	264	4.5%
C82-C85, C96	Non-Hodgkin lymphoma	234	4.0%
C56	Ovary	196	3.3%

FIGURE 11: THE 10 LEADING SITES OF CANCER IN ALL GENDER




TABLE 9: THE 10 LEADING SITES OF CANCER IN MALES

ICD-10	PRIMARY SITE (Short title used)	NO.	% IN MALES
C33-C34	Bronchus and lung	410	14.7%
C22	Liver	331	11.9%
C18-C20	Colon and Rectum	271	9.7%
C15	Esophagus	173	6.2%
C01-C06	Oral cavity	168	6.0%
C61	Prostate	161	5.8%
C82-C85, C96	Non-Hodgkin lymphoma	147	5.3%
C32	Larynx	99	3.6%
C67	Bladder	78	2.8%
C44	Skin (excluded melanoma)	64	2.3%

FIGURE 12: THE 10 LEADING SITES OF CANCER IN MALES




FIGURE 13: TRENDS OF FIVE LEADING SITES IN MALES: NUMBER




TABLE 10: THE 10 LEADING SITES OF CANCER IN FEMALES

ICD-10	PRIMARY SITE (Short title used)	NO.	% IN FEMALES
C50	Breast	698	22.6%
C53	Cervix uteri	377	12.2%
C73	Thyroid	297	9.6%
C33-C34	Bronchus and lung	214	6.9%
C18-C20	Colon and Rectum	211	6.8%
C56	Ovary	196	6.3%
C54	Corpus uteri	186	6.0%
C22	Liver	137	4.4%
C82-C85, C96	NHL	89	2.9%
C44	Skin(excluded melanoma)	55	1.8%

FIGURE 14: THE 10 LEADING SITES OF CANCER IN FEMALES




FIGURE 15: TRENDS OF FIVE LEADING SITES IN FEMALES: NUMBER




TABLE 11: MALIGNANCY IN CHILDHOOD (AGE 0-14 YEARS) *

SITE	GROUP (ICCC-3 division)	BOY	GIRL	ALL	
		NO.	NO.	NO.	%
I	Leukemias, myeloproliferative diseases, and myelodysplastic diseases	22	15	37	28.9%
II	Lymphomas and reticuloendothelial neoplasms	12	6	18	14.1%
III	CNS and miscellaneous intracranial and intraspinal neoplasms	11	11	22	17.2%
IV	Neuroblastoma and other peripheral nervous cell tumors	2	2	4	3.1%
V	Retinoblastoma	4	1	5	3.9%
VI	Renal tumors	3	2	5	3.9%
VII	Hepatic tumors	3	1	4	3.1%
VIII	Malignant bone tumors	3	6	9	7.0%
IX	Soft tissue and other extraosseous sarcomas	2	4	6	4.7%
X	Germ cell tumors, trophoblastic tumors, and neoplasms of gonads	4	3	7	5.5%
XI	Other malignant epithelial neoplasms and malignant melanomas	3	7	10	7.8%
XII	Other and unspecified malignant neoplasms	1	0	1	0.8%
	Total	70	58	128	100.0%

The malignancy in childhood was 2.2% of all new cancer patients.

* Childhood site group according to International Classification of Childhood Cancer, Third edition (ICCC-3)

FIGURE 16: AGE DISTRIBUTION OF ALL MALIGNANCIES IN CHILDHOOD



Age; Mean = 7.2, Median = 7

COMMON CANCERS

ORAL CAVITY CANCER

ICD-10 C01-C06

FIGURE 17: DISTRIBUTION OF SUBSITES




TABLE 12: STAGING

STAGE	MALE	FEMALE	TOTAL	%
Stage I	10	11	21	8.0%
Stage II	29	10	39	14.8%
Stage III	21	5	26	9.8%
Stage IV	121	39	160	60.6%
Not specified	12	6	18	6.8%
Total	193	71	264	100.0%

ESOPHAGEAL CANCER

ICD-10 C15

FIGURE 18: DISTRIBUTION OF SUBSITES IN MALES AND FEMALES




TABLE 13: STAGING

STAGE	MALE	FEMALE	TOTAL	%
Stage I	5	0	5	2.6%
Stage II	18	4	22	11.6%
Stage III	61	5	66	34.9%
Stage IV	28	3	31	16.4%
Not specified	61	4	65	34.4%
Total	173	16	189	100.0%

COLON AND RECTUM CANCER

ICD-10 C18-20

FIGURE 19: DISTRIBUTION OF SUBSITES IN MALES AND FEMALES





TABLE 14: STAGING

STAGE	MALE	FEMALE	TOTAL	%
Stage I	8	9	17	3.5%
Stage II	66	28	94	19.5%
Stage III	88	75	163	33.8%
Stage IV	63	48	111	23.0%
Not specified	46	51	97	20.1%
Total	271	211	482	100.0%

FIGURE 20: STAGING TRENDS: PERCENTAGE



LUNG CANCER

ICD-10 C34

FIGURE 21: DISTRIBUTION OF SUBSITES IN MALE AND FEMALE




TABLE 15: STAGING

STAGE	MALE	FEMALE	TOTAL	%
Stage I	11	7	18	2.9%
Stage II	16	6	22	3.5%
Stage III	60	17	77	12.3%
Stage IV	256	152	408	65.4%
Not specified	67	32	99	15.9%
Total	410	214	624	100.0%

BREAST CANCER (EXCLUDING IN SITU)

ICD-10 C50

FIGURE 22: DISTRIBUTION OF SUBSITES IN FEMALE BREAST





TABLE 16: STAGING

STAGE	MALE	FEMALE	TOTAL	%
Stage I	1	94	95	13.6%
Stage II	1	236	237	33.9%
Stage III	0	234	234	33.4%
Stage IV	0	59	59	8.4%
Not specified	0	75	75	10.7%
Total	2	698	700	100.0%

FIGURE 23: STAGING TRENDS OF FEMALE BREAST CANCER: PERCENTAGE



CERVICAL CANCER (EXCLUDING IN SITU)

ICD-10 C53

TABLE 17: STAGING

STAGE	NUMBER	%
Stage I	72	19.1%
Stage II	131	34.7%
Stage III	127	33.7%
Stage IV	35	9.3%
Not specified	12	3.2%
Total	377	100.0%

FIGURE 24: STAGING TRENDS OF CERVICAL CANCER: PERCENTAGE




TABLE 18: SEX AND AGE DISTRIBUTION ACCORDING TO PRIMARY SITE

PRIMARY SITE (ICD-10)	GENDER	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Lip	All gender	3	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0	0
(C00)	Male	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	male	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0
Tongue	All gender	133	0	0	0	0	0	1	5	11	9	15	15	13	17	13	12	11	5	6
(C01-C02)	Male	97	0	0	0	0	0	0	2	5	7	12	13	11	15	9	9	7	3	4
	male	36	0	0	0	0	0	1	3	6	2	3	2	2	2	4	3	4	2	2
Mouth	All gender	131	0	0	1	0	1	1	0	2	7	7	12	13	23	14	8	14	13	15
(C03-C06)	Male	96	0	0	0	0	0	0	0	2	6	7	12	10	18	11	6	10	7	7
	male	35	0	0	1	0	1	1	0	0	1	0	0	3	5	3	2	4	6	8
Salivary gland	All gender	30	0	0	1	0	1	0	2	1	2	7	3	0	2	4	4	1	1	1
(C07-C08)	Male	12	0	0	1	0	0	0	1	0	0	3	1	0	1	1	2	1	1	0
	male	18	0	0	0	0	1	0	1	1	2	4	2	0	1	3	2	0	0	1
Tonsil	All gender	49	0	0	0	0	0	0	0	1	2	2	8	5	9	5	4	3	8	2
(C09)	Male	44	0	0	0	0	0	0	0	1	2	2	8	5	9	5	3	3	4	2
	male	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	0

PRIMARY SITE (ICD-10)	GENDER	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Oropharynx	All gender	22	0	0	0	0	0	0	0	1	1	5	3	3	1	5	1	1	1	0
(C10)	Male	22	0	0	0	0	0	0	0	1	1	5	3	3	1	5	1	1	1	0
	male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Nasopharynx	All gender	121	0	1	0	4	4	3	3	11	12	16	15	14	10	14	7	4	2	1
(C11)	Male	95	0	1	0	4	3	3	2	7	9	12	13	11	10	10	5	3	1	1
	male	26	0	0	0	0	1	0	1	4	3	4	2	3	0	4	2	1	1	0
Hypopharynx	All gender	68	0	0	0	0	0	0	0	1	4	7	9	7	10	8	7	5	6	4
(C12-C13)	Male	65	0	0	0	0	0	0	0	1	4	7	9	7	10	6	7	5	5	4
	male	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0
Pharynx, unspecified	All gender	18	0	0	0	0	1	0	1	0	0	3	1	5	3	1	2	0	1	0
(C14)	Male	11	0	0	0	0	1	0	1	0	0	2	1	3	2	1	0	0	0	0
	male	7	0	0	0	0	0	0	0	0	0	1	0	2	1	0	2	0	1	0
Esophagus	All gender	189	0	0	0	0	0	0	1	0	5	13	19	32	25	29	28	21	12	4
(C15)	Male	173	0	0	0	0	0	0	1	0	5	12	19	32	22	27	25	17	11	2
	male	16	0	0	0	0	0	0	0	0	0	1	0	0	3	2	3	4	1	2

PRIMARY SITE (ICD-10)	GENDER	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Stomach	All gender	81	0	0	0	0	1	0	1	3	5	6	12	10	14	13	3	6	4	3
(C16)	Male	55	0	0	0	0	1	0	1	1	4	4	10	8	9	8	1	6	2	0
	male	26	0	0	0	0	0	0	0	2	1	2	2	2	5	5	2	0	2	3
Small intestine	All gender	13	0	0	0	1	0	0	0	0	0	0	1	2	1	3	1	3	1	0
(C17)	Male	9	0	0	0	0	0	0	0	0	0	0	0	2	1	3	1	2	0	0
	male	4	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	1	1	0
Colon	All gender	210	0	0	1	0	0	0	3	6	11	11	14	29	27	32	22	27	15	12
(C18)	Male	110	0	0	0	0	0	0	2	0	1	5	8	13	15	20	15	15	7	9
	male	100	0	0	1	0	0	0	1	6	10	6	6	16	12	12	7	12	8	3
Rectum	Both sex	272	0	0	0	0	1	2	7	6	6	19	34	37	36	46	34	21	16	7
(C19-C20)	Male	161	0	0	0	0	0	1	4	3	3	7	24	20	21	32	20	14	8	4
	male	111	0	0	0	0	1	1	3	3	3	12	10	17	15	14	14	7	8	3
Anus	All gender	14	0	0	0	0	0	0	1	2	2	1	0	1	2	0	2	1	1	1
(C21)	Male	9	0	0	0	0	0	0	1	1	1	0	0	1	1	0	2	1	0	1
	male	5	0	0	0	0	0	0	0	1	1	1	0	0	1	0	0	0	1	0

PRIMARY SITE (ICD-10)	GENDER	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Liver	All gender	468	4	0	0	0	0	2	3	12	27	32	54	73	84	66	50	26	27	8
(C22)	Male	331	3	0	0	0	0	1	3	9	22	28	37	58	65	48	31	14	9	3
	male	137	1	0	0	0	0	1	0	3	5	4	17	15	19	18	19	12	18	5
Gallbladder etc.	All gender	63	0	0	0	0	0	1	4	3	0	3	5	6	6	12	7	6	4	6
(C23-C24)	Male	23	0	0	0	0	0	0	0	0	0	1	1	2	3	5	4	3	1	3
	male	40	0	0	0	0	0	1	4	3	0	2	4	4	3	7	3	3	3	3
Pancreas	All gender	89	0	0	0	0	0	0	0	1	5	3	7	18	12	12	11	11	6	3
(C25)	Male	44	0	0	0	0	0	0	0	0	3	2	1	9	5	7	6	7	3	1
	male	45	0	0	0	0	0	0	0	1	2	1	6	9	7	5	5	4	3	2
Nose, sinuses etc.	All gender	33	1	0	0	0	0	2	1	3	3	4	4	5	1	3	3	1	0	2
(C30-C31)	Male	20	1	0	0	0	0	0	1	1	2	4	3	3	0	2	1	0	0	2
	male	13	0	0	0	0	0	2	0	2	1	0	1	2	1	1	2	1	0	0
Larynx	All gender	102	0	0	0	0	0	1	1	0	4	4	10	22	13	17	16	5	5	4
(C32)	Male	99	0	0	0	0	0	0	1	0	4	4	10	22	13	17	15	5	5	3
	male	3	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	1

PRIMARY SITE (ICD-10)	GENDER	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Trachea, bronchus and lung	All gender	624	0	0	0	0	2	0	4	10	25	29	53	108	89	103	60	82	35	24
(C33-C34)	Male	410	0	0	0	0	1	0	2	6	15	20	37	71	58	66	35	64	16	19
	male	214	0	0	0	0	1	0	2	4	10	9	16	37	31	37	25	18	19	5
Other thoracic organs	All gender	14	1	1	0	1	4	0	0	1	0	1	4	0	0	0	1	0	0	0
(C37-C38)	Male	9	1	1	0	1	4	0	0	1	0	0	0	0	0	0	1	0	0	0
	male	5	0	0	0	0	0	0	0	0	0	1	4	0	0	0	0	0	0	0
Bone	All gender	31	0	4	5	0	2	2	4	0	0	4	3	0	2	0	0	2	2	1
(C40-C41)	Male	15	0	2	1	0	2	1	3	0	0	2	0	0	2	0	0	2	0	0
	male	16	0	2	4	0	0	1	1	0	0	2	3	0	0	0	0	0	2	1
Melanoma of skin	All gender	25	0	0	1	0	0	1	0	0	1	0	2	2	4	5	0	3	3	3
(C43)	Male	13	0	0	1	0	0	0	0	0	0	0	0	2	4	3	0	0	1	2
	male	12	0	0	0	0	0	1	0	0	1	0	2	0	0	2	0	3	2	1
Other skin	All gender	105	1	0	1	2	0	3	2	3	2	6	5	13	6	12	12	12	14	11
(C44)	Male	50	0	0	1	0	0	2	1	2	2	4	1	8	4	2	6	7	4	6
	male	55	1	0	0	2	0	1	1	1	0	2	4	5	2	10	6	5	10	5

PRIMARY SITE (ICD-10)	GENDER	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Kaposi sarcoma	All gender	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
(C46)	Male	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Connective and soft tissues	All gender	73	2	0	1	3	5	3	7	10	6	3	6	9	3	4	5	2	3	1
(C47, C49)	Male	41	0	0	0	2	4	3	4	6	2	2	2	5	2	4	1	1	2	1
	male	32	2	0	1	1	1	0	3	4	4	1	4	4	1	0	4	1	1	0
Breast	All gender	700	0	0	0	0	0	10	29	42	82	130	119	88	93	44	28	24	6	5
(C50)	Male	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
	male	698	0	0	0	0	0	10	29	42	82	130	119	88	93	43	28	24	5	5
Vulva	All gender	18	0	0	0	0	0	1	0	0	1	0	1	2	2	0	2	5	1	3
(C51)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	male	18	0	0	0	0	0	1	0	0	1	0	1	2	2	0	2	5	1	3
Vagina	All gender	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0
(C52)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	male	3	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0

PRIMARY SITE (ICD-10)	GENDER	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Cervix uteri	All gender	377	0	0	0	0	1	6	15	38	46	56	53	51	41	28	17	9	11	5
(C53)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	male	377	0	0	0	0	1	6	15	38	46	56	53	51	41	28	17	9	11	5
Corpus uteri	All gender	186	0	0	0	0	0	2	2	10	11	12	32	35	30	28	14	6	4	0
(C54)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	male	186	0	0	0	0	0	2	2	10	11	12	32	35	30	28	14	6	4	0
Uterus unspecified	All gender	18	0	0	0	0	0	0	2	0	1	4	2	3	3	3	0	0	0	0
(C55)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	male	18	0	0	0	0	0	0	2	0	1	4	2	3	3	3	0	0	0	0
Ovary	All gender	196	1	1	2	3	8	6	8	10	20	25	23	18	26	14	16	7	5	3
(C56)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	male	196	1	1	2	3	8	6	8	10	20	25	23	18	26	14	16	7	5	3
Other male genital	All gender	4	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0
(C57)	Male	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	male	4	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0	0

[illegible]

[illegible]

[illegible]

PRIMARY SITE (ICD-10)	GENDER	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
Hodgkin lymphoma	All gender	29	0	0	3	2	5	3	1	0	2	0	3	5	0	0	3	1	0	1
(C81)	Male	10	0	0	2	1	1	1	0	0	1	0	2	2	0	0	0	0	0	0
	male	19	0	0	1	1	4	2	1	0	1	0	1	3	0	0	3	1	0	1
Non-Hodgkin lymphoma	All gender	234	0	3	9	3	9	8	3	10	11	20	26	28	29	22	14	14	12	13
(C82-C85, C96)	Male	147	0	3	6	2	2	5	2	6	11	12	17	20	17	15	5	8	9	7
	male	87	0	0	3	1	7	3	1	4	0	8	9	8	12	7	9	6	3	6
Multiple myeloma	All gender	46	0	0	0	0	0	0	1	1	2	4	6	4	4	12	11	1	0	0
(C90)	Male	24	0	0	0	0	0	0	1	1	2	0	4	2	1	6	6	1	0	0
	male	22	0	0	0	0	0	0	0	0	0	4	2	2	3	6	5	0	0	0
Lymphoid leukemia	All gender	41	11	9	3	1	0	0	3	1	1	0	1	3	2	4	1	1	0	0
(C91)	Male	23	5	6	2	1	0	0	2	0	1	0	1	1	1	1	1	1	0	0
	male	18	6	3	1	0	0	0	1	1	0	0	0	2	1	3	0	0	0	0
Myeloid leukemia	All gender	69	4	2	4	2	2	1	8	2	2	4	6	11	5	7	3	3	2	1
(C92-C94)	Male	35	3	2	2	0	2	1	4	0	1	4	1	3	2	4	3	1	1	1
	male	34	1	0	2	2	0	0	4	2	1	0	5	8	3	3	0	2	1	0

[illegible]

PRIMARY SITE (ICD-10)	GENDER	Total	<5	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+
All sites	All gender	5,881	48	29	51	38	75	100	166	254	383	530	650	763	747	696	491	408	279	173
	Male	2,787	25	22	24	19	29	29	49	69	133	189	263	378	378	402	275	258	148	97
	Female	3,094	23	7	27	19	46	71	117	185	250	341	387	385	369	294	216	150	131	76

TABLE 19: HISTOLOGICAL TYPES

PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
Lip			1	2	3
(C00)	8070	Squamous cell carcinoma, NOS	1	2	3
Tongue			97	36	133
(C01-C02)	8000	Neoplasm, malignant	3	1	4
	8051	Verrucous carcinoma, NOS	0	2	2
	8070	Squamous cell carcinoma, NOS	94	32	126
	8200	Adenoid cystic carcinoma	0	1	1
Mouth			96	35	131
(C03-C06)	8000	Neoplasm, malignant	1	0	1
	8010	Carcinoma, NOS	1	0	1
	8051	Verrucous carcinoma, NOS	1	1	2
	8070	Squamous cell carcinoma, NOS	89	30	119
	8071	Squamous cell carcinoma, keratinizing, NOS	1	0	1
	8083	Basaloid squamous cell carcinoma	1	0	1
	8200	Adenoid cystic carcinoma	1	1	2
	8430	Mucoepidermoid carcinoma	1	2	3
	8720	Malignant melanoma, NOS	0	1	1
Salivary gland			12	18	30
(C07-C08)	8000	Neoplasm, malignant	1	1	2
	8010	Carcinoma, NOS	1	2	3
	8070	Squamous cell carcinoma, NOS	2	2	4
	8082	Lymphoepithelial carcinoma	0	1	1
	8140	Adenocarcinoma, NOS	0	2	2
	8200	Adenoid cystic carcinoma	4	5	9
	8430	Mucoepidermoid carcinoma	3	5	8
	8550	Acinar cell carcinoma	1	0	1



PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
Tonsil			44	5	49
(C09)	8010	Carcinoma, NOS	1	0	1
	8041	Small cell carcinoma, NOS	1	0	1
	8070	Squamous cell carcinoma, NOS	42	5	47
Oropharynx			22	0	22
(C10)	8070	Squamous cell carcinoma, NOS	22	0	22
Nasopharynx			95	26	121
(C11)	8000	Neoplasm, malignant	2	2	4
	8010	Carcinoma, NOS	3	0	3
	8020	Carcinoma, undifferentiated, NOS	24	6	30
	8070	Squamous cell carcinoma, NOS	33	7	40
	8071	Squamous cell carcinoma, keratinizing, NOS	1	0	1
	8072	Squamous cell carc.large cell,nonkeratinizing, NOS	32	11	43
Hypopharynx			65	3	68
(C12-C13)	8000	Clinical, no microscopic confirmation	2	0	2
	8010	Carcinoma, NOS	1	0	1
	8070	Squamous cell carcinoma, NOS	62	3	65
Pharynx, unspecified			11	7	18
(C14)	8000	Clinical, no microscopic confirmation	1	0	1
	8020	Carcinoma, undifferentiated, NOS	1	0	1
	8051	Verrucous carcinoma, NOS	0	1	1
	8070	Squamous cell carcinoma, NOS	9	6	15
Esophagus			173	16	189
(C15)	8000	Clinical, no microscopic confirmation	4	1	5
	8004	Malignant tumor, spindle cell type	1	0	1
	8010	Carcinoma, NOS	2	0	2
	8032	Spindle cell carcinoma, NOS	1	0	1
	8041	Small cell carcinoma, NOS	1	0	1
	8070	Squamous cell carcinoma, NOS	152	11	163
	8140	Adenocarcinoma, NOS	10	4	14

PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
	8560	Adenosquamous carcinoma	1	0	1
	8980	Carcinosarcoma, NOS	1	0	1
Stomach			55	26	81
(C16)	8000	Neoplasm, malignant	2	3	5
	8010	Carcinoma, NOS	1	1	2
	8140	Adenocarcinoma, NOS	47	16	63
	8490	Signet ring cell carcinoma	5	5	10
	9000	Brenner tumor, malignant	0	1	1
Small intestine			9	4	13
(C17)	8000	clinical, no microscopic confirmation	0	1	1
	8010	Carcinoma, NOS	1	0	1
	8140	Adenocarcinoma, NOS	7	2	9
	8240	Carcinoid tumor, NOS	1	0	1
	8480	Mucinous adenocarcinoma	0	1	1
Colon			110	100	210
(C18)	8000	Clinical, no microscopic confirmation	5	8	13
	8010	Carcinoma, NOS	2	2	4
	8140	Adenocarcinoma, NOS	96	81	177
	8240	Carcinoid tumor, NOS	1	0	1
	8480	Mucinous adenocarcinoma	5	5	10
	8490	Signet ring cell carcinoma	1	1	2
	8830	Malignant fibrous histiocyoma	0	1	1
	8890	Leiomyosarcoma, NOS	0	1	1
	9044	Clear cell sarcoma, NOS (except of kidney)	0	1	1
Rectum			161	111	272
(C19-C20)	8000	Neoplasm, malignant	5	2	7
	8010	Carcinoma, NOS	3	1	4
	8140	Adenocarcinoma, NOS	146	102	248
	8240	Carcinoid tumor, NOS	1	2	3
	8480	Mucinous adenocarcinoma	3	2	5
	8490	Signet ring cell carcinoma	3	2	5



PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
Anus			9	5	14
(C21)	8010	Carcinoma, NOS	1	0	1
	8070	Squamous cell carcinoma, NOS	3	0	3
	8140	Adenocarcinoma, NOS	5	5	10
Liver			331	137	468
(C22)	8000	Clinical, no microscopic confirmation	261	89	350
	8000	Neoplasm, malignant	2	2	4
	8010	Carcinoma, NOS	1	0	1
	8041	Small cell carcinoma, NOS	1	0	1
	8140	Adenocarcinoma, NOS	9	15	24
	8160	Cholangiocarcinoma	8	12	20
	8170	Hepatocellular carcinoma, NOS	45	14	59
		Combined hepatocellular carcinoma/cholangiocarcinoma	2	0	2
	8180		2	0	2
	8246	Neuroendocrine carcinoma, NOS	0	1	1
	8481	Mucin-producing adenocarcinoma	0	1	1
	8910	Embryonal rhabdomyosarcoma, NOS	0	1	1
	8970	Hepatoblastoma	2	1	3
	9120	Hemangiosarcoma	0	1	1
Gallbladder etc.			23	40	63
(C23-C24)	8000	Clinical, no microscopic confirmation	3	2	5
	8000	Neoplasm, malignant	1	0	1
	8140	Adenocarcinoma, NOS	17	32	49
	8160	Cholangiocarcinoma	1	3	4
	8246	Neuroendocrine carcinoma, NOS	1	1	2
	8480	Mucinous adenocarcinoma	0	1	1
	8801	Spindle cell sarcoma	0	1	1
Pancreas			44	45	89
(C25)	8000	Clinical, no microscopic confirmation	19	10	29
	8000	Neoplasm, malignant	2	0	2
	8010	Carcinoma, NOS	1	4	5



PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
	8041	Small cell carcinoma, NOS	0	2	2
	8140	Adenocarcinoma, NOS	18	25	43
	8240	Carcinoid tumor, NOS	1	3	4
	8246	Neuroendocrine carcinoma, NOS	2	0	2
	8480	Mucinous adenocarcinoma	1	1	2
Nose, sinuses etc.			20	13	33
(C30-C31)	8000	Neoplasm, malignant	1	0	1
	8041	Small cell carcinoma, NOS	1	1	2
	8070	Squamous cell carcinoma, NOS	7	5	12
	8071	Squamous cell carcinoma, keratinizing, NOS	1	1	2
	8072	Squamous cell carc.large cell,nonkeratinizing, NOS	1	0	1
	8200	Adenoid cystic carcinoma	0	2	2
	8246	Neuroendocrine carcinoma, NOS	2	0	2
	8260	Papillary adenocarcinoma	1	0	1
	8430	Mucoepidermoid carcinoma	1	0	1
	8550	Acinar cell carcinoma	1	0	1
	8720	Malignant melanoma, NOS	2	0	2
	8910	Embryonal rhabdomyosarcoma, NOS	0	1	1
	8920	Alveolar rhabdomyosarcoma	1	1	2
	9522	Olfactory neuroblastoma	1	2	3
Larynx			99	3	102
(C32)	8000	Clinical, no microscopic confirmation	2	0	2
	8070	Squamous cell carcinoma, NOS	96	3	99
	8071	Squamous cell carcinoma, keratinizing, NOS	1	0	1
Trachea, bronchus and lung			410	214	624
	8000	Clinical, no microscopic confirmation	37	22	59
(C33-C34)	8000	Neoplasm, malignant	11	6	17
	8010	Carcinoma, NOS	10	0	10
	8012	Large cell carcinoma, NOS	2	1	3
	8033	Pseudosarcomatous carcinoma	1	0	1
	8041	Small cell carcinoma, NOS	32	10	42
	8045	Combined small cell carcinoma	1	0	1



PRIMARY SITE (ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
	8046	Non-small cell carcinoma	35	9	44
	8070	Squamous cell carcinoma, NOS	63	6	69
	8071	Squamous cell carcinoma, keratinizing, NOS	1	0	1
	8074	Sarcomatoid carcinoma, squamous cell	1	0	1
	8140	Adenocarcinoma, NOS	207	151	358
	8141	Scirrhous adenocarcinoma	0	1	1
	8240	Carcinoid tumor, NOS	2	0	2
	8246	Neuroendocrine carcinoma, NOS	4	1	5
	8250	Bronchiolo-alveolar adenocarcinoma, NOS	1	3	4
	8430	Mucoepidermoid carcinoma	0	2	2
	8560	Adenosquamous carcinoma	2	1	3
	8815	Solitary fibrous tumor, malignant	0	1	1
Other thoracic organs			9	5	14
(C37-C38)	8000	Clinical, no microscopic confirmation	1	1	2
	8041	Small cell carcinoma, NOS	1	0	1
	8140	Adenocarcinoma, NOS	0	1	1
	8580	Thymoma, malignant, NOS	1	0	1
	8586	Thymic carcinoma, NOS	0	2	2
	8858	Dedifferentiated liposarcoma	0	1	1
	9061	Seminoma, NOS	1	0	1
	9064	Germinoma	3	0	3
	9071	Endodermal sinus tumor (Yolk sac tumor)	1	0	1
	9080	Immature teratoma, malignant	1	0	1
Bone			15	16	31
(C40-C41)	8000	Clinical, no microscopic confirmation	2	3	5
	9180	Osteosarcoma, NOS	5	7	12
	9186	Central osteosarcoma	3	2	5
	9220	Chondrosarcoma, NOS	4	1	5
	9240	Mesenchymal chondrosarcoma	0	1	1
	9370	Chordoma, NOS	1	2	3



PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
Melanoma of skin			13	12	25
(C43)	8720	Malignant melanoma, NOS	11	12	23
	8721	Nodular melanoma	1	0	1
	8771	Epithelioid cell melanoma	1	0	1
Other skin			50	55	105
(C44)	8000	Clinical, no microscopic confirmation	1	1	2
	8000	Neoplasm, malignant	1	0	1
	8010	Carcinoma, NOS	0	1	1
	8070	Squamous cell carcinoma, NOS	19	16	35
	8090	Basal cell carcinoma, NOS	22	30	52
	8094	Basosquamous carcinoma	1	0	1
	8410	Sebaceous adenocarcinoma	1	0	1
	8542	Paget disease, extramammary (ex. Paget dis.of bone)	0	1	1
	8832	Dermatofibrosarcoma, NOS	5	6	11
Kaposi sarcoma			1	0	1
(C46)	9140	Kaposi sarcoma	1	0	1
Connective and soft tissues			41	32	73
(C47, C49)	8000	Clinical, no microscopic confirmation	1	2	3
	8000	Neoplasm, malignant	1	2	3
	8004	Malignant tumor, spindle cell type	1	0	1
	8800	Sarcoma, NOS	2	2	4
	8801	Spindle cell sarcoma	10	1	11
	8802	Pleomorphic sarcoma	1	2	3
	8804	Epithelioid sarcoma	1	0	1
	8810	Fibrosarcoma, NOS	1	0	1
	8811	Fibromyxosarcoma	1	2	3
	8830	Malignant fibrous histiocytoma	4	2	6
	8850	Liposarcoma, NOS	3	1	4
	8851	Liposarcoma, well differentiated	0	1	1
	8852	Myxoid liposarcoma	2	2	4
	8854	Pleomorphic liposarcoma	2	0	2
	8858	Dedifferentiated liposarcoma	1	1	2



PRIMARY SITE (ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
	8890	Leiomyosarcoma, NOS	1	6	7
	8901	Pleomorphic rhabdomyosarcoma, adult type	1	0	1
	8910	Embryonal rhabdomyosarcoma, NOS	0	1	1
	8920	Alveolar rhabdomyosarcoma	0	1	1
	9040	Synovial sarcoma, NOS	5	2	7
	9071	Endodermal sinus tumor (Yolk sac tumor)	0	1	1
	9120	Hemangiosarcoma	0	2	2
		Malignant peripheral nerve sheath tumorMeningeal			
	9540	sarcomatosis	1	0	1
	9560	Neurilemoma, malignant	1	1	2
	9581	Alveolar soft part sarcoma	1	0	1
Breast			2	698	700
(C50)	8000	Clinical, no microscopic confirmation	0	10	10
	8000	Neoplasm, malignant	0	2	2
	8004	Malignant tumor, spindle cell type	0	1	1
	8010	Carcinoma, NOS	0	20	20
	8020	Carcinoma, undifferentiated, NOS	0	1	1
	8050	Papillary carcinoma, NOS	0	4	4
	8140	Adenocarcinoma, NOS	0	6	6
	8260	Papillary adenocarcinoma	0	1	1
	8341	Papillary microcarcinoma	0	3	3
	8343	Papillary carcinoma, encapsulated	0	1	1
	8452	Solid pseudopapillary carcinoma	0	1	1
	8480	Mucinous adenocarcinoma	0	10	10
	8500	Infiltrating duct carcinoma, NOS	2	593	595
	8504	Intracystic carcinoma, NOS	0	1	1
	8510	Medullary carcinoma, NOS	0	1	1
	8520	Lobular carcinoma, NOS	0	25	25
	8522	Infiltrating duct and lobular carcinoma	0	6	6
	8523	Infiltrating duct mixed with other carcinoma	0	9	9
	8575	Metaplastic carcinoma, NOS	0	1	1
	9020	Phyllodes tumor, malignant	0	1	1
	9120	Hemangiosarcoma	0	1	1

PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
Vulva			0	18	18
(C51)	8070	Squamous cell carcinoma, NOS	0	13	13
	8090	Basal cell carcinoma, NOS	0	1	1
	8542	Paget disease, extramammary (ex. Paget dis.of bone)	0	2	2
	8720	Malignant melanoma, NOS	0	2	2
Vagina			0	3	3
(C52)	8000	Neoplasm, malignant	0	1	1
	8070	Squamous cell carcinoma, NOS	0	2	2
Cervix uteri			0	377	377
(C53)	8000	Clinical, no microscopic confirmation	0	3	3
	8000	Neoplasm, malignant	0	1	1
	8010	Carcinoma, NOS	0	8	8
	8013	Large cell neuroendocrine carcinoma	0	1	1
	8020	Carcinoma, undifferentiated, NOS	0	1	1
	8041	Small cell carcinoma, NOS	0	2	2
	8052	Papillary squamous cell carcinoma	0	2	2
	8070	Squamous cell carcinoma, NOS	0	186	186
	8071	Squamous cell carcinoma, keratinizing, NOS	0	17	17
	8072	Squamous cell carc.large cell,nonkeratinizing, NOS	0	37	37
	8076	Squamous cell carcinoma, microinvasive	0	8	8
	8140	Adenocarcinoma, NOS	0	72	72
	8246	Neuroendocrine carcinoma, NOS	0	5	5
	8270	Chromophobe carcinoma	0	1	1
	8310	Clear cell adenocarcinoma, NOS	0	6	6
	8323	Mixed cell adenocarcinoma	0	2	2
	8380	Endometrioid adenocarcinoma, NOS	0	5	5
	8384	Adenocarcinoma, endocervical type	0	2	2
	8480	Mucinous adenocarcinoma	0	3	3
	8481	Mucin-producing adenocarcinoma	0	1	1
	8560	Adenosquamous carcinoma	0	14	14



PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
Corpus uteri			0	186	186
(C54)	8000	Clinical, no microscopic confirmation	0	2	2
	8010	Carcinoma, NOS	0	4	4
	8032	Spindle cell carcinoma, NOS	0	1	1
	8041	Small cell carcinoma, NOS	0	1	1
	8140	Adenocarcinoma, NOS	0	2	2
	8244	Combined carcinoid and adenocarcinoma	0	1	1
	8310	Clear cell adenocarcinoma, NOS	0	4	4
	8323	Mixed cell adenocarcinoma	0	9	9
	8380	Endometrioid adenocarcinoma, NOS	0	147	147
	8441	Serous cystadenocarcinoma, NOS	0	6	6
	8480	Mucinous adenocarcinoma	0	1	1
	8930	Endometrial stromal sarcoma, NOS	0	3	3
	8931	Endometrial stromal sarcoma, low grade	0	5	5
Uterus unspecified			0	18	18
(C55)	8800	Sarcoma, NOS	0	2	2
	8890	Leiomyosarcoma, NOS	0	4	4
	8901	Pleomorphic rhabdomyosarcoma, adult type	0	1	1
	8933	Adenosarcoma	0	2	2
	8980	Carcinosarcoma, NOS	0	9	9
Ovary			0	196	196
(C56)	8000	Clinical, no microscopic confirmation	0	8	8
	8000	Neoplasm, malignant	0	2	2
	8010	Carcinoma, NOS	0	4	4
	8020	Carcinoma, undifferentiated, NOS	0	1	1
	8070	Squamous cell carcinoma, NOS	0	5	5
	8140	Adenocarcinoma, NOS	0	28	28
	8310	Clear cell adenocarcinoma, NOS	0	19	19
	8323	Mixed cell adenocarcinoma	0	5	5
	8380	Endometrioid adenocarcinoma, NOS	0	32	32
	8441	Serous cystadenocarcinoma, NOS	0	39	39
	8470	Mucinous cystadenocarcinoma, NOS	0	4	4
	8480	Mucinous adenocarcinoma	0	18	18



PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
	8481	Mucin-producing adenocarcinoma	0	1	1
	8560	Adenosquamous carcinoma	0	1	1
	8574	Adenocarcinoma, neuroendocrine differentiation	0	1	1
	8576	Hepatoid adenocarcinoma	0	1	1
	8890	Leiomyosarcoma, NOS	0	2	2
	8901	Pleomorphic rhabdomyosarcoma, adult type	0	1	1
	8980	Carcinosarcoma, NOS	0	3	3
	9060	Dysgerminoma	0	6	6
	9071	Endodermal sinus tumor (Yolk sac tumor)	0	3	3
	9080	Immature teratoma, malignant	0	10	10
	9085	Mixed germ cell tumor	0	1	1
	9471	Desmoplastic nodular medulloblastoma	0	1	1
Other female genital			0	4	4
(C57)	8000	Neoplasm, malignant	0	1	1
	8010	Carcinoma, NOS	0	1	1
	8441	Serous cystadenocarcinoma, NOS	0	1	1
	8890	Leiomyosarcoma, NOS	0	1	1
Placenta			0	4	4
(C58)	9100	Choriocarcinoma, NOS		4	4
Penis			13	0	13
(C60)	8000	Clinical, no microscopic confirmation	1	0	1
	8070	Squamous cell carcinoma, NOS	12	0	12
Prostate			161	0	161
(C61)	8000	Clinical, no microscopic confirmation	12	0	12
	8000	Neoplasm, malignant	2	0	2
	8010	Carcinoma, NOS	4	0	4
	8140	Adenocarcinoma, NOS	142	0	142
	8550	Acinar cell carcinoma	1	0	1



PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
Testis			14	0	14
(C62)	8910	Embryonal rhabdomyosarcoma, NOS	1	0	1
	9061	Seminoma, NOS	5	0	5
	9064	Germinoma	1	0	1
	9071	Endodermal sinus tumor (Yolk sac tumor)	4	0	4
	9085	Mixed germ cell tumor	3	0	3
Kidney			54	23	77
(C64)	8000	Clinical, no microscopic confirmation	10	3	13
	8000	Neoplasm, malignant	2	0	2
	8120	Transitional cell carcinoma, NOS	2	1	3
	8130	Papillary transitional cell carcinoma	2	1	3
	8140	Adenocarcinoma, NOS	2	1	3
	8260	Papillary adenocarcinoma	4	2	6
	8312	Renal cell carcinoma, NOS	30	13	43
	8960	Nephroblastoma, NOS	2	2	4
Renal pelvis			3	2	5
(C65)	8000	Clinical, no microscopic confirmation	1	1	2
	8120	Transitional cell carcinoma, NOS	2	1	3
Ureter			2	0	2
(C66)	8120	Transitional cell carcinoma, NOS	1	0	1
	8130	Papillary transitional cell carcinoma	1	0	1
Bladder			78	12	90
(C67)	8000	Clinical, no microscopic confirmation	2	0	2
	8000	Neoplasm, malignant	1	1	2
	8010	Carcinoma, NOS	2	0	2
	8020	Carcinoma, undifferentiated, NOS	1	0	1
	8033	Pseudosarcomatous carcinoma	1	0	1
	8070	Squamous cell carcinoma, NOS	0	1	1
	8120	Transitional cell carcinoma, NOS	52	3	55
	8130	Papillary transitional cell carcinoma	18	4	22
	8131	Transitional cell carcinoma, micropapillary	0	1	1



PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
	8140	Adenocarcinoma, NOS	1	1	2
	8801	Spindle cell sarcoma	0	1	1
Urinary system, NOS			1	0	1
(C68)	8010	Carcinoma, NOS	1	0	1
Eye			9	5	14
(C69)	8000	Clinical, no microscopic confirmation	1	0	1
	8070	Squamous cell carcinoma, NOS	3	3	6
	8720	Malignant melanoma, NOS	1	1	2
	9510	Retinoblastoma, NOS	4	1	5
Brain, nervous system			55	34	89
(C70-C72)	8000	Clinical, no microscopic confirmation	4	0	4
	8000	Neoplasm, malignant	1	0	1
	9064	Germinoma	2	1	3
	9364	Peripheral neuroectodermal tumor	1	0	1
	9380	Glioma, malignant	2	0	2
	9382	Mixed glioma	0	1	1
	9391	Ependymoma, NOS	0	2	2
	9392	Ependymoma, anaplastic	2	0	2
	9400	Astrocytoma, NOS	6	8	14
	9401	Astrocytoma, anaplastic	7	5	12
	9411	Gemistocytic astrocytoma	1	0	1
	9440	Glioblastoma, NOS	16	9	25
	9442	Gliosarcoma	1	1	2
	9450	Oligodendroglioma, NOS	1	0	1
	9451	Oligodendroglioma, anaplastic	1	1	2
	9470	Medulloblastoma, NOS	6	3	9
	9471	Desmoplastic nodular medulloblastoma	1	0	1
	9473	Primitive neuroectodermal tumor, NOS	0	1	1
	9500	Neuroblastoma, NOS	3	1	4
	9530	Meningioma, malignant	0	1	1



PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
Thyroid			61	297	358
(C73)	8000	Clinical, no microscopic confirmation	0	3	3
	8000	Neoplasm, malignant	4	5	9
	8010	Carcinoma, NOS	2	6	8
	8021	Carcinoma, anaplastic, NOS	2	4	6
	8260	Papillary adenocarcinoma	39	211	250
	8330	Follicular adenocarcinoma, NOS	7	37	44
	8335	Follicular carcinoma, minimally invasive	0	1	1
	8337	Insular carcinoma	0	1	1
	8340	Papillary carcinoma, follicular variant	4	16	20
	8341	Papillary microcarcinoma	3	11	14
	8510	Medullary carcinoma, NOS	0	2	2
Adrenal gland			7	2	9
(C74)	8010	Carcinoma, NOS	1	0	1
	8140	Adenocarcinoma, NOS	1	0	1
	8370	Adrenal cortical carcinoma	3	0	3
	9500	Neuroblastoma, NOS	2	2	4
Other endocrine			0	1	1
(C75)	8000	Clinical, no microscopic confirmation	0	1	1
Hodgkin lymphoma			10	19	29
(C81)	9650	Hodgkin lymphoma, NOS	0	2	2
	9651	Hodgkin lymphoma, lymphocyte-rich	1	1	2
	9652	Hodgkin lymphoma, mixed cellularity, NOS	3	5	8
	9663	Hodgkin lymphoma, nodular sclerosis, NOS	6	11	17
Non-Hodgkin lymphoma			147	87	234
(C82-C85)	9590	Malignant lymphoma, NOS	2	2	4
	9591	Malignant lymphoma, non-Hodgkin, NOS	5	1	6
	9670	Malignant lymphoma, small B lymphocytic, NOS	2	0	2
	9673	Mantle cell lymphoma	4	0	4
	9680	Malignant lymphoma, large B-cell, diffuse, NOS	80	65	145
	9684	Malig.lymphoma,large B-cell,diffuse,immunoblas.NOS	1	0	1



PRIMARY SITE (ICD-10)			MALE	FEMALE	ALL
	9687	Burkitt lymphoma, NOS	5	0	5
	9690	Follicular lymphoma, NOS	2	2	4
	9691	Follicular lymphoma, grade 2	1	0	1
	9695	Follicular lymphoma, grade 1	1	1	2
	9698	Follicular lymphoma, grade 3	3	1	4
	9699	Marginal zone B-cell lymphoma, NOS	15	5	20
	9700	Mycosis fungoides	1	0	1
	9702	Peripheral T-cell lymphoma, NOS	6	3	9
	9705	Angioimmunoblastic T-cell lymphoma	6	3	9
	9708	Subcutaneous panniculitis-like T-cell lymphoma	0	1	1
	9709	Cutaneous T-cell lymphoma, NOS	7	2	9
	9714	Anaplastic large cell lymphoma, T cell/Null cell type	2	0	2
	9718	Primary cutaneous CD30+ T-cell lymphoprolif.disorder	1	1	2
	9719	NK/T-cell lymphoma, nasal and nasal-type	3	0	3
Multiple myeloma			24	22	46
(C90)	9731	Plasmacytoma, NOS	5	2	7
	9732	Multiple myeloma	19	20	39
Lymphoid leukemia			23	18	41
		B-cell chronic lymphocytic leukemia/small			
(C91)	9823	lymphocyt.lymphoma	4	5	9
	9835	Acute lymphoblastic leukemia, NOS	19	13	32
Myeloid leukemia			35	34	69
(C92-C94)	9861	Acute myeloid leukemia, NOS	28	27	55
	9863	Chronic myeloid leukemia, NOS	5	6	11
	9867	Acute myelomonocytic leukemia	1	0	1
	9910	Acute megakaryoblastic leukemia	0	1	1
	9945	Chronic myelomonocytic leukemia, NOS	1	0	1
Leukemia unspecified			5	2	7
(C95)	9800	Leukemia, NOS	1	0	1
	9801	Acute leukemia, NOS	4	2	6



PRIMARY SITE					
(ICD-10)	CODE	MORPHOLOGY	MALE	FEMALE	ALL
Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue			2	2	4
(C96)	9751	Langerhans cell histiocytosis, NOS	2	2	4
Other & unspecified			58	62	120
(C26, C39, C42, C48, C76, C77, C80, C88)	8000	Clinical, no microscopic confirmation	8	11	19
	8000	Neoplasm, malignant	4	7	11
	8004	Malignant tumor, spindle cell type	0	1	1
	8010	Carcinoma, NOS	12	2	14
	8012	Large cell carcinoma, NOS	2	0	2
	8020	Carcinoma, undifferentiated, NOS	1	1	2
	8032	Spindle cell carcinoma, NOS	0	1	1
	8070	Squamous cell carcinoma, NOS	14	1	15
	8071	Squamous cell carcinoma, keratinizing, NOS	2	0	2
	8140	Adenocarcinoma, NOS	13	24	37
	8240	Carcinoid tumor, NOS	1	0	1
	8246	Neuroendocrine carcinoma, NOS	1	2	3
	8260	Papillary adenocarcinoma	0	1	1
	8441	Serous cystadenocarcinoma, NOS	0	5	5
	8480	Mucinous adenocarcinoma	0	2	2
	8850	Liposarcoma, NOS	0	1	1
	8890	Leiomyosarcoma, NOS	0	1	1
	9071	Endodermal sinus tumor (Yolk sac tumor)	0	1	1
	9473	Primitive neuroectodermal tumor, NOS	0	1	1
MDS			2	2	4
D46	9989	Myelodysplastic syndrome, NOS	2	2	4
MPD			5	0	5
D47	9960	Chronic myeloproliferative disease, NOS	2	0	2
	9962	Essential thrombocythemia	2	0	2
	9964	Chronic eosinophilic leukemia, NOS	1	0	1

APPENDIX: DEFINITIONS

BRAIN TUMOR	Excluding meningeal and cranial nerve tumor.
CANCER CASE	Excluding in situ neoplasms.
CODING	Topography according to the ICD-10, and morphology according to the ICD-O, third edition, coding in childhood based on International Classification of Childhood Cancer, Third edition (ICCC-3).
NEW CASE	Cancer case diagnosed at Songklanagarind Hospital or referred to Songklanagarind Hospital in the year reported.
NOS.	Not Otherwise Specified.